{"url_path":"/sec/hcwb/8-k/2026-06-01/item-3-01","section_key":"item-3-01","section_title":"Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-01","source_url":"https://www.sec.gov/Archives/edgar/data/1828673/0001493152-26-026529-index.html","accession_number":"0001493152-26-026529","cik":"0001828673","ticker":"HCWB","issuer_name":"HCW Biologics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1828673/0001493152-26-026529-index.html","primary_entity_key":"0001828673","primary_entity_name":"HCW Biologics Inc."},"word_count":417,"has_tables":true,"body_markdown":"**Item\n3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**\n\n** **\n\nAs\npreviously disclosed, on March 26, 2026, HCW Biologics Inc. (the “Company”) received written notice from the Listing Qualifications\nStaff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) that for\n30 consecutive business days, the Company’s listed securities did not maintain a minimum bid price of $1 per share, in accordance\nwith Nasdaq Listing Rule 5550(a)(2) (“Bid Price Rule”) for continued listing on The Nasdaq Capital Market (the “Exchange”).\nDue to the fact that the Company effected a 1-for-40 reverse stock split on April 11, 2025, the Company was not afforded a 180-calendar\nday period to demonstrate compliance.\n\n \n\nOn\nMay 29, 2026, the Nasdaq Hearings Panel (“the Panel”) granted the Company an extension in which to regain compliance\nwith continued listing rules of the Exchange. The Panel’s determination follows the Company’s hearing on May 5, 2026, at\nwhich the Company presented, and the Panel considered, the Company’s plan to regain compliance with the Bid Price Rule. The Panel\ngranted the Company’s request for continued listing on the Exchange, subject to, among other things, that on or before July 29,\n2026, the Company must demonstrate compliance with the Bid Price Rule by exhibiting a bid price at or above $1 for twenty consecutive\ntrading days.\n\n \n\nThe\nPanel also noted that if the Company becomes deficient with the Bid Price Rule prior to September 22, 2026, the Company will be immediately\ndelisted. Further, if the Company becomes non-compliant with any other listing rule prior to September 22, 2026, the Company will be\nallowed seven calendar days to advise the Panel on its plan to cure the listing deficiencies and the Panel will, at that time, determine\nwhether to grant the Company an exception to cure the deficiency.\n\n \n\nThe\nPanel also required that Company provide prompt notification of any significant events that occur during the exception period that may\naffect the Company’s compliance with Nasdaq requirements. If the Company regains compliance and satisfies the terms of the exception,\nthe Panel intends to impose a Discretionary Panel Monitor on the Company for an additional one-year period, pursuant to Listing Rule\n5815(d)(4)(A).\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n** **\n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**HCW BIOLOGICS INC.**\n\n \n \n \n\nDate: June 1, 2026\nBy:\n*/s/\nHing C. Wong*\n\n \n \nHing C. Wong, Founder and Chief Executive Officer"}